세계의 암 치료용 생물학적 제제 시장 규모 조사 및 예측 : 제품별, 용도별, 유통채널별, 지역별 분석(2023-2030년)

Global Cancer Biologics Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Cancer biologics refer to a class of drugs that are designed to target specific molecules or pathways involved in the growth and spread of cancer cells. They are typically derived from living organisms, such as proteins, antibodies, and vaccines, and are designed to interact with specific targets on cancer cells. These drugs are often used in the treatment of various types of cancer and may be used alone or in combination with other treatments, such as chemotherapy, radiation therapy, or surgery. Cancer biologics may also be referred to as biologic therapies, biotherapeutics, or targeted therapies. The major driving factors for the Global Cancer Biologics Market are increasing incidences of cancer and increasing demand for targeted and personalized medicine. Moreover, technological advancements and favorable regulatory environment are creating lucrative growth opportunities in the market over the forecast period 2023-2030.

The rising incidences of cancer are one of the primary drivers of the cancer biologics market. Globally, the number of new cases of cancer was 19.3 million in 2020, according to the GLOBOCAN 2020 statistics. This number is expected to increase to 30.2 million by 2040. This significant rise in cancer cases underscores the urgent need for effective cancer treatments, including small molecule drugs, which have shown promise in the treatment of various types of cancer. However, the high cost of Cancer Biologics stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cancer Biologics Market study include: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. The North American market for cancer biologics is expected to be the largest due to the presence of major pharmaceutical companies, high healthcare expenditure, and increasing cancer prevalence. The US is expected to dominate the market due to the high adoption rate of advanced cancer treatments. The Asia-Pacific market for cancer biologics is expected to witness significant growth due to factors such as increasing cancer prevalence, improving healthcare infrastructure, and increasing investment in R&D. China and Japan are expected to be the major contributors to the market growth.

Major market players included in this report are:

• Roche Holding AG
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• AstraZeneca plc
• Eli Lilly and Company
• AbbVie Inc.

Recent Developments in the Market:

• In January 2020, F. Hoffmann-La Roche AG announced that it had submitted a supplemental biological license application to the U.S. Food and Drug Administration (FDA) for Tecentriq (atezolizumab), in combination with the drug Avastin (bevacizumab), for the treatment of the most common form of liver cancer.

Global Cancer Biologics Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Product, Application, Distribution Channel, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Product:

• Monoclonal Antibodies
• Cytokine-Based Immunotherapy
• Cancer Vaccines
• CAR-T Cell Therapy
• Immune Checkpoint Inhibitors

By Application:

• Non-small Cell Lung Cancer
• Prostate Cancer
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Others

By Distribution Channel:

• Hospitals
• Clinics
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Cancer Biologics Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Cancer Biologics Market, by Product, 2020-2030 (USD Billion)
  • 1.2.3. Cancer Biologics Market, by Application, 2020-2030 (USD Billion)
  • 1.2.4. Cancer Biologics Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Cancer Biologics Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Cancer Biologics Market Dynamics

• 3.1. Cancer Biologics Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing Incidence of cancer
    • 3.1.1.2. Increasing demand for targeted and personalized medicine
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Cancer Biologics
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Technological advancements
    • 3.1.3.2. Favorable regulatory environment

Chapter 4. Global Cancer Biologics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Cancer Biologics Market, by Product

• 5.1. Market Snapshot
• 5.2. Global Cancer Biologics Market by Product, Performance - Potential Analysis
• 5.3. Global Cancer Biologics Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 5.4. Cancer Biologics Market, Sub Segment Analysis
  • 5.4.1. Monoclonal Antibodies
  • 5.4.2. Cytokine-Based Immunotherapy
  • 5.4.3. Cancer Vaccines
  • 5.4.4. CAR-T Cell Therapy
  • 5.4.5. Immune Checkpoint Inhibitors

Chapter 6. Global Cancer Biologics Market, by Application

• 6.1. Market Snapshot
• 6.2. Global Cancer Biologics Market by Application, Performance - Potential Analysis
• 6.3. Global Cancer Biologics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 6.4. Cancer Biologics Market, Sub Segment Analysis
  • 6.4.1. Non-small Cell Lung Cancer
  • 6.4.2. Prostate Cancer
  • 6.4.3. Breast Cancer
  • 6.4.4. Acute Myeloid Leukemia
  • 6.4.5. Lymphoma
  • 6.4.6. Others

Chapter 7. Global Cancer Biologics Market, by Distribution Channel

• 7.1. Market Snapshot
• 7.2. Global Cancer Biologics Market by Distribution Channel, Performance - Potential Analysis
• 7.3. Global Cancer Biologics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 7.4. Cancer Biologics Market, Sub Segment Analysis
  • 7.4.1. Hospitals
  • 7.4.2. Clinics
  • 7.4.3. Others

Chapter 8. Global Cancer Biologics Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Cancer Biologics Market, Regional Market Snapshot
• 8.4. North America Cancer Biologics Market
  • 8.4.1. U.S. Cancer Biologics Market
    • 8.4.1.1. Product breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Cancer Biologics Market
• 8.5. Europe Cancer Biologics Market Snapshot
  • 8.5.1. U.K. Cancer Biologics Market
  • 8.5.2. Germany Cancer Biologics Market
  • 8.5.3. France Cancer Biologics Market
  • 8.5.4. Spain Cancer Biologics Market
  • 8.5.5. Italy Cancer Biologics Market
  • 8.5.6. Rest of Europe Cancer Biologics Market
• 8.6. Asia-Pacific Cancer Biologics Market Snapshot
  • 8.6.1. China Cancer Biologics Market
  • 8.6.2. India Cancer Biologics Market
  • 8.6.3. Japan Cancer Biologics Market
  • 8.6.4. Australia Cancer Biologics Market
  • 8.6.5. South Korea Cancer Biologics Market
  • 8.6.6. Rest of Asia Pacific Cancer Biologics Market
• 8.7. Latin America Cancer Biologics Market Snapshot
  • 8.7.1. Brazil Cancer Biologics Market
  • 8.7.2. Mexico Cancer Biologics Market
• 8.8. Middle East & Africa Cancer Biologics Market
  • 8.8.1. Saudi Arabia Cancer Biologics Market
  • 8.8.2. South Africa Cancer Biologics Market
  • 8.8.3. Rest of Middle East & Africa Cancer Biologics Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Roche Holding AG
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Novartis AG
  • 9.3.3. Merck & Co., Inc.
  • 9.3.4. Bristol-Myers Squibb Company
  • 9.3.5. Amgen Inc.
  • 9.3.6. Johnson & Johnson
  • 9.3.7. Pfizer Inc.
  • 9.3.8. AstraZeneca plc
  • 9.3.9. Eli Lilly and Company
  • 9.3.10. AbbVie Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption